aeruginosa

polymicrobial biofilms as determined by CFU (A) and MTT (B) assays. The biofilms were developed in 24-well cell culture plates and the effectiveness MCC950 research buy of antimicrobial drug(s) treatment was assessed by the reduction of CFUs and A570 values. Each S3I-201 order experiment was performed two different times with the clinical isolates AF53470 and PA56402 using independently prepared conidial suspensions and bacterial cultures, and one time with the laboratory isolates AF36607 and PA27853. Similar results were obtained for both set of isolates. The data were analyzed by two-way ANOVA with Bonferroni post test analysis by comparing each treatment group to the other for statistical significance using Graphpad Prism 5.0. The vertical bar on each data point denotes standard error of the mean for two experiments performed with AF53470 and PA56402. Legends: AF, A. fumigatus monomicrobial biofilm; AF + PA, A. fumigatus-P. aeruginosa polymicrobial biofilm; VCZ, voriconazole; CEF, cefepime. Figure 4B shows the effectiveness find more of voriconazole

alone and in combination with cefepime against A. fumigatus monomicrobial and A. fumigatus-P. aeruginosa polymicrobial biofilms as determined by MTT assay. A comparison of the A570 values obtained for monomicrobial and polymicrobial biofilms as a function of voriconazole concentration showed that the polymicrobial biofilm is less susceptible to the fungicidal activity of the antifungal drug (P < 0.01). Similarly, voriconazole in combination with cefepime was less active against polymicrobial biofilm compared to the activity against monomicrobial biofilm (P < 0.01). This finding is contrary to what was obtained in the

CFU assay where both monomicrobial and polymicrobial biofilms of A. fumigatus was almost equally susceptible to voriconazole with and without cefepime. Thus, the apparent resistance of A. fumigatus in polymicrobial biofilm to voriconazole may be an artifact of the MTT assay due to the presence of P. aeruginosa cells not susceptible to voriconazole but actively contributing to tetrazolium reduction in the polymicrobial biofilms. In support of this suggestion it was noted that a comparison of the effect of voriconazole alone and in combination with cefepime against monomicrobial biofilm is very similar (P > 0.05). Similarly, the effect check of voriconazole alone and in combination with cefepime against A. fumigatus-P. aeruginosa biofilm is almost identical (P > 0.05) showing no significant difference. Thus, since there is no suitable way of separating the fungal and the bacterial contributions to the tetrazolium reduction the MTT assay is unsuitable for studying the bioactivity of voriconazole against A. fumigatus biofilm. Figure 5 shows the effects of cefepime and posaconazole individually and in combination on monomicrobial and polymicrobial biofilms of P. aeruginosa and A. fumigatus. A comparison of the susceptibilities of A. fumigatus monomicrobial and A. fumigatus-P.